Hesperetin

Pharmacology & Research

Hesperetin is the flavanone aglycone of hesperidin — and it is the species the body actually absorbs. Dietary hesperidin is a rutinoside that must first be de-sugared by colonic microbiota before hesperetin can enter circulation, which is why this molecule earns its own page: it owns the pharmacokinetics of the absorbed, active form. Two facts shape its evidence. First, there is essentially no monotherapy human efficacy trial of isolated hesperetin — the cardiovascular and metabolic human data usually attributed to it are really hesperidin or orange-juice trials, which live on the hesperidin page. Second, its circulating phase-II conjugates are not inert: hesperetin-7-O-glucuronide reproduces vascular and hypotensive activity ^{6Reference 6Yamamoto M et al. · 2013Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-3’-O-glucuronide, exerts hypotensive, vasodilatory and anti-inflammatory activitiesView study →}, so “circulating hesperetin” means bioactive conjugates. Its strongest signal is mechanistic — endothelial eNOS/nitric-oxide stimulation ^{5Reference 5Rizza S et al. · 2011Clinical trialCitrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndromeView study →} and Nrf2 antioxidant activation ^{10Reference 102021Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K/AKT–Nrf2–ARE pathwayView study →}.

1. Endothelial / vascular

Hesperetin is the species behind citrus’s vascular signal. In endothelial cells the aglycone (not the glycoside) stimulates nitric-oxide production and Akt/eNOS activation ^{5Reference 5Rizza S et al. · 2011Clinical trialCitrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndromeView study →}, and the major circulating human metabolite hesperetin-7-O-glucuronide — but not the 3’-O-glucuronide — reproduces vasodilatory and hypotensive activity, showing the conjugate is itself active ^{6Reference 6Yamamoto M et al. · 2013Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-3’-O-glucuronide, exerts hypotensive, vasodilatory and anti-inflammatory activitiesView study →}.

Gap: the human clinical endpoints (flow-mediated dilation, blood pressure) were all tested as hesperidin or orange juice and live on hesperidin; there is no blood-pressure or hard-outcome RCT of isolated hesperetin ^{5,6Reference 5Rizza S et al. · 2011Clinical trialCitrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndromeView study →Reference 6Yamamoto M et al. · 2013Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-3’-O-glucuronide, exerts hypotensive, vasodilatory and anti-inflammatory activitiesView study →}.

2. Metabolic / insulin resistance

The RESHES randomised trial reversed insulin resistance in overweight/obese subjects — but hesperetin was co-administered with trans-resveratrol, so the effect is not attributable to hesperetin alone ^{7Reference 7Kang I et al. · 2021Reversal of insulin resistance in overweight and obese subjects by trans-resveratrol and hesperetin combination (RESHES trial)View study →}. A systematic review of citrus flavanones on diabetes is suggestive but pools glycoside, aglycone and juice ^{8Reference 82023Systematic reviewEffect of citrus flavanones on diabetes: a systematic reviewView study →}; in vitro, hesperetin outperforms hesperidin on antidiabetic and antioxidant endpoints, consistent with the aglycone being the active form ^{9Reference 9Ali AM et al. · 2020In-vitro evaluation of the antidiabetic potential of hesperidin and its aglycone hesperetin under oxidative stressView study →}.

Gap: no monotherapy human trial of hesperetin, and the glucose meta-analyses for the glycoside are null (see the hesperidin page) ^{7,8Reference 7Kang I et al. · 2021Reversal of insulin resistance in overweight and obese subjects by trans-resveratrol and hesperetin combination (RESHES trial)View study →Reference 82023Systematic reviewEffect of citrus flavanones on diabetes: a systematic reviewView study →}.

3. Anti-inflammatory / antioxidant

Robust and reproducible preclinically: hesperetin activates the PI3K/AKT–Nrf2–ARE axis to blunt hepatic oxidative stress and inflammation ^{10Reference 102021Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K/AKT–Nrf2–ARE pathwayView study →}, inhibits NLRP3 inflammasome activation and pyroptosis in spinal-cord-injury models ^{11Reference 112023Hesperetin ameliorates spinal-cord injury by inhibiting NLRP3 inflammasome activation and pyroptosisView study →}, and engages Nrf2/ARE against isoproterenol-induced cardiac hypertrophy ^{12Reference 122020Targeting the Nrf2/ARE signalling pathway to mitigate isoproterenol-induced cardiac hypertrophy: plausible role of hesperetinView study →}.

Gap: entirely rodent/cell, at supraphysiologic free-aglycone concentrations well above the low, heavily-conjugated human plasma exposure; no human anti-inflammatory trial of the isolate ^{10,4Reference 102021Hesperetin ameliorates hepatic oxidative stress and inflammation via the PI3K/AKT–Nrf2–ARE pathwayView study →Reference 4Najmanová I et al. · 2020The pharmacokinetics of flavanonesView study →}.

4. Neuroprotective

A dedicated review compiles hesperetin’s neurodegeneration-relevant actions — antioxidant, anti-neuroinflammatory, and greater blood-brain-barrier permeability than the glycoside — across Alzheimer’s, Parkinson’s and ischaemia models ^{13Reference 13Justin Thenmozhi A et al. · 2022Neuroprotective effects and therapeutic potential of the citrus flavonoid hesperetin in neurodegenerative diseasesView study →}.

Gap: review and animal work only; no clinical neurological data, and human-relevant dosing is unestablished ^{13Reference 13Justin Thenmozhi A et al. · 2022Neuroprotective effects and therapeutic potential of the citrus flavonoid hesperetin in neurodegenerative diseasesView study →}.

5. Anticancer

Cell studies and reviews describe cell-cycle arrest, apoptosis induction and, for example, Notch1-pathway activation driving differentiation and apoptosis in cancer lines ^{14,15Reference 14Ferreira de Oliveira JMP et al. · 2020Therapeutic potential of hesperidin and its aglycone hesperetin: cell-cycle regulation and apoptosis induction in cancer modelsView study →Reference 15Ning Y et al. · 2014Hesperetin activates the Notch1 signalling cascade, causes apoptosis and induces cellular differentiation in anaplastic thyroid cancerView study →}.

Gap: in-vitro/animal, at high micromolar concentrations, with no in-vivo tumour-outcome or clinical evidence — a preclinical curiosity, not a therapeutic claim ^{14,15Reference 14Ferreira de Oliveira JMP et al. · 2020Therapeutic potential of hesperidin and its aglycone hesperetin: cell-cycle regulation and apoptosis induction in cancer modelsView study →Reference 15Ning Y et al. · 2014Hesperetin activates the Notch1 signalling cascade, causes apoptosis and induces cellular differentiation in anaplastic thyroid cancerView study →}.

6. Antiviral (in-silico)

Hesperetin recurs as a hit in computational SARS-CoV-2 main-protease (Mpro/3CLpro) docking screens and flavonoid-antiviral reviews ^{16,17Reference 16Tallei TE et al. · 2020Recognition of natural products as potential inhibitors of COVID-19 main protease (Mpro): in-silico evidenceView study →Reference 17Russo M et al. · 2020Roles of flavonoids against coronavirus infectionView study →}.

Gap: these are in-silico predictions and narrative reviews — there is no enzyme-assay-confirmed potency of isolated hesperetin and no clinical benefit; included only as a labelled computational signal ^{16,17Reference 16Tallei TE et al. · 2020Recognition of natural products as potential inhibitors of COVID-19 main protease (Mpro): in-silico evidenceView study →Reference 17Russo M et al. · 2020Roles of flavonoids against coronavirus infectionView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Endothelial Akt → eNOS / NO	↑ endothelial nitric oxide, vasodilation (aglycone-driven, in vitro)	endothelial function, BP
Hesperetin-7-O-glucuronide (circulating conjugate)	regioselectively vasoactive/hypotensive — the metabolite is bioactive	vascular; PK–activity link
Nrf2 / ARE via PI3K–AKT	↑ antioxidant/cytoprotective genes; ↓ oxidative stress	antioxidant, hepato/cardio-protection
NLRP3 inflammasome / NF-κB	↓ inflammasome activation, ↓ cytokines	anti-inflammatory, injury models
Cell-cycle / apoptosis (incl. Notch1)	growth arrest, pro-apoptotic signalling	anticancer (preclinical)
CYP3A / P-glycoprotein inhibition	↓ first-pass metabolism/efflux of co-substrates (rat/in-vitro)	drug-interaction plausibility

Pharmacokinetics

This is the load-bearing section and the reason the aglycone deserves its own page. Hesperetin is the actually-absorbed and circulating species — dietary hesperidin only enters the body after its rutinose is stripped by colonic microbiota. Direct human pharmacokinetics of the aglycone exist: after single oral doses of the free aglycone, hesperetin appears in plasma with measurable Tmax/Cmax and is eliminated within about 24 hours ^{1Reference 1Kanaze FI et al. · 2007Clinical trialPharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjectsView study →}, and earlier work quantified plasma kinetics and urinary excretion after citrus intake ^{2Reference 2Erlund I et al. · 2001Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juiceView study →}. Removing the sugar relocates and raises absorption — α-rhamnosidase-treated (deglycosylated) orange juice markedly increases and accelerates flavanone absorption versus native juice, direct human confirmation that the rhamnose cap is the bottleneck ^{3Reference 3Bredsdorff L et al. · 2010Clinical trialAbsorption, conjugation and excretion of the flavanones naringenin and hesperetin from α-rhamnosidase-treated orange juice in human subjectsView study →} (the controlled rutinoside-vs-glucoside comparison is detailed on the hesperidin page). Absorbed hesperetin is then almost entirely glucuronidated and sulfated, so free aglycone in plasma is minimal — but the conjugates are not inert (hesperetin-7-O-glucuronide is vasoactive ^{6Reference 6Yamamoto M et al. · 2013Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-3’-O-glucuronide, exerts hypotensive, vasodilatory and anti-inflammatory activitiesView study →}), and a flavanone-PK review contextualises the low, saturable, formulation- and microbiome-dependent bioavailability ^{4Reference 4Najmanová I et al. · 2020The pharmacokinetics of flavanonesView study →}. A milligram figure without the form and matrix says little.

Clinical trials

There is essentially no monotherapy human efficacy trial of isolated hesperetin. The human record splits into pharmacokinetic studies that do use the aglycone or deglycosylated forms ^{1,2,3Reference 1Kanaze FI et al. · 2007Clinical trialPharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjectsView study →Reference 2Erlund I et al. · 2001Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juiceView study →Reference 3Bredsdorff L et al. · 2010Clinical trialAbsorption, conjugation and excretion of the flavanones naringenin and hesperetin from α-rhamnosidase-treated orange juice in human subjectsView study →}, and the RESHES RCT, which included hesperetin but combined with trans-resveratrol, so it cannot isolate hesperetin’s contribution ^{7Reference 7Kang I et al. · 2021Reversal of insulin resistance in overweight and obese subjects by trans-resveratrol and hesperetin combination (RESHES trial)View study →}. The frequently-cited “hesperetin” cardiovascular and metabolic human data are actually hesperidin or orange-juice trials and belong to hesperidin.

Last checked: July 2026.

Toxicity & Safety

Hesperetin is a dietary citrus flavanone with a long consumption history and low apparent toxicity. A regulatory-style program (mutagenicity, acute and subchronic toxicity) of a hesperetin-7-glucoside–β-cyclodextrin complex reported no genotoxicity and a favourable safety margin ^{19Reference 192023Mutagenic, acute and subchronic toxicity studies of the hesperetin-7-glucoside–β-cyclodextrin inclusion complexView study →}, and comprehensive reviews covering its toxicology, pharmacology and bioavailability find no signal of meaningful human toxicity at dietary or supplemental exposure ^{20,21Reference 202024Recent advances in the biosynthesis, bioavailability, toxicology, pharmacology and controlled release of hesperetinView study →Reference 212024ReviewComprehensive review of hesperetin: advancements in pharmacokinetics, pharmacological effects and novel formulationsView study →}. No human toxic dose is established.

On interactions, one point matters: the clinically important grapefruit–drug interaction is caused by furanocoumarins, not flavanones — hesperetin (a sweet-orange flavanone) does not inherit grapefruit’s warning. It does inhibit CYP3A and P-glycoprotein in rat and in-vitro models and raised felodipine exposure ^{18Reference 18Sridhar V et al. · 2014In vitroEvaluation of first-pass CYP3A and P-glycoprotein activities using felodipine and hesperetin in Wistar rats and everted rat gut sacs in vitroView study →} — biologically plausible but clinically unproven, and at free-aglycone concentrations rarely reached from dietary intake given first-pass conjugation. A reasonable, conservative caution applies to concentrated extracts taken with narrow-therapeutic-index CYP3A4/P-gp substrates, and alongside anticoagulant or antiplatelet therapy. Do not overstate.

Dosage

There is no established human dose of isolated hesperetin. Human pharmacokinetic studies used single oral doses of the free aglycone (study-specific, not therapeutic) ^{1Reference 1Kanaze FI et al. · 2007Clinical trialPharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjectsView study →}, and the one efficacy-adjacent human trial (RESHES) used hesperetin as part of a resveratrol-plus-hesperetin combination, so no clean hesperetin dose can be extracted ^{7Reference 7Kang I et al. · 2021Reversal of insulin resistance in overweight and obese subjects by trans-resveratrol and hesperetin combination (RESHES trial)View study →}. Delivered exposure depends on form (free aglycone or glucoside versus rutinoside) and heavy first-pass conjugation. Nothing here is a recommendation.

References